自体造血干细胞移植治疗儿童难治性自身免疫性疾病
单中心研究纳入7例难治性自身免疫病患儿接受自体造血干细胞移植,中位随访17年,中位无进展生存4.2年、总生存17年,全部存活且临床缓解,4例仍需免疫治疗;3例感染、2例新发自身免疫病等安全性事件。
要点
- 7例患儿接受自体造血干细胞移植,中位随访17年全部存活且临床缓解。
- 中位无进展生存4.2年(95%CI 0.98-8.3),总生存17年(95%CI 11.8-22.1)。
- 3例感染、2例新发自身免疫病、1例环磷酰胺相关短暂肾衰和心包积液。
核心结论
- 自体造血干细胞移植对儿童和青少年难治性自身免疫性疾病是一种有效且安全的方法。
- 移植适应证和时机需仔细考虑并采用多学科方法。
研究设计与样本
- 单中心研究,连续纳入接受自体造血干细胞移植的难治性自身免疫病儿童和青少年,共7例。
- 收集人口学、临床、实验室特征、移植前用药、疾病活动度和功能状态。
- 主要结局为无进展生存,次要结局包括总生存、疾病特异性治疗反应、末次随访时疾病活动和移植安全性。
主要发现
- 纳入7例:系统性硬化症2例、全硬化性斑状硬皮病1例、嗜酸性筋膜炎1例、幼年皮肌炎1例、全身型幼年特发性关节炎2例;女性4例、男性3例,移植时中位年龄10岁(7-19),移植后中位随访17年。
- 中位无进展生存4.2年(95%CI 0.98-8.3),中位总生存17年(95%CI 11.8-22.1);移植后1年和2年无进展生存率分别为100%和77%。
- 所有患儿均存活,所有患者处于临床缓解,仅4例需要持续免疫治疗。
- 安全性:3例发生感染(HHV6、念珠菌和罗尔斯顿菌脓毒症);1例发生全身炎症反应综合征;2例新发继发性自身免疫病(自身免疫性溶血性贫血、Graves病);1例发现乳腺纤维腺瘤。
- 治疗毒性:1例环磷酰胺相关短暂肾功能衰竭和心包积液;1例闭经/不孕。
临床怎么用
- 作者认为自体造血干细胞移植是儿童和青少年难治性自身免疫性疾病有效且安全的方法。
- 作者认为移植适应证和时机需仔细考虑并采用多学科方法。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the long-term effectiveness and safety of autologous haematopoiesis stem cell transplantation (AHSCT) for severe, refractory autoimmune diseases in paediatric patients. METHODS: A single-centre study of consecutive children and adolescents with refractory autoimmune diseases undergoing AHSCT was performed. Demographics, clinical, laboratory features, pre-AHSCT medications, disease activity and functional status were captured. The primary outcome was progression-free survival, secondary outcomes included overall survival, disease-specific treatment responses, disease activity at the last follow-up and AHSCT safety. RESULTS: The study included seven patients: two systemic sclerosis, one pansclerotic morphoea, one eosinophilic fasciitis, one juvenile dermatomyositis and two patients with systemic juvenile idiopathic arthritis; four women, three men median age at AHSCT of 10 years (7-19), median follow-up post-AHSCT of 17 years. Median progression-free survival and overall survival was 4.2 years (95% CI: 0.98 to 8.3) and 17 years (95% CI: 11.8 to 22.1), respectively. Progression-free survival rates at 1 and 2 years post-AHSCT were 100% and 77%, respectively. All children survived. All patients are in clinical remission, only four require ongoing immunotherapy. SAFETY: Three experienced infections, including HHV6, Candida and Ralstonia sepsis; one developed a systemic inflammatory response syndrome; two new onset secondary autoimmune diseases including autoimmune haemolytic anaemia, Graves' disease and one was found to have a breast fibroadenoma. Treatment toxicity: one cyclophosphamide-associated transient renal failure and pericardial effusion, one patient with amenorrhoea/infertility. CONCLUSIONS: AHSCT was an effective and safe approach for children and adolescents with treatment-refractory autoimmune diseases. The indication and timing of transplantation requires a careful consideration and a multidisciplinary approach.
引用
- Satirer Ö, Henes JC, Döring M, et al. Autologous haematopoiesis stem cell transplantation (AHSCT) for treatment-refractory autoimmune diseases in children. RMD Open. 2024. PMID: 39004431. doi:10.1136/rmdopen-2024-004381
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。